2014•Clinical Cosmetic and Investigational DermatologyOpen access

Ustekinumab for the treatment of psoriatic arthritis: an update

Faranak Kamangar, Parastoo Davari, Nasim Fazel, Michael S. Leo

Abstract

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ustekinumab, Psoriatic arthritis, Medicine, Food and drug administration, Psoriasis, Dermatology, Clinical trial, Arthritis